Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 6,533 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Subject Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of Orally Administered BPM31510 in Healthy Subjects

NCT02486055
View directory record Official record
Conditions
Healthy
Interventions
BPM31510 Oral Nanosuspension 4%
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

NCT03137134
View directory record Official record
Conditions
Healthy
Interventions
Crizotinib, Esomeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence and Food Effect of 250mg of Lamotrigine XR

NCT00605371
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine tablet, Lamotrigine caplet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

NCT00618709
View directory record Official record
Conditions
Healthy
Interventions
ATX-101
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

NCT01806909
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-H5-Vtn
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probing the Role of Feature Dimension Maps in Visual Cognition: Impact of Working Memory Maintenance (Expt 2.3)

NCT06733467
View directory record Official record
Conditions
Basic Science: Visual Attention in Healthy Participants, Basic Science: Neural Representations of Location
Interventions
Stimulus properties: remembered feature
Other
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

NCT06270511
View directory record Official record
Conditions
Healthy Volunteers
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

NCT01998646
View directory record Official record
Conditions
Pharmacokinetics of ASP4058, Healthy Subjects, Food Effect of ASP4058
Interventions
ASP4058, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miami, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 21, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Renal Mechanism of Action/Splay vs. TmG

NCT00726505
View directory record Official record
Conditions
Diabetes, NOS
Interventions
Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)

NCT06772805
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of COR388

NCT03418688
View directory record Official record
Conditions
Alzheimer Disease
Interventions
COR388, Placebo
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
San Diego, California • Orlando, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers

NCT00332956
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rFIV vaccine, rF1V vaccine, rF1V vaccine 160 mcg given on Study Days 0, 56, 182
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

NCT04075175
View directory record Official record
Conditions
Diphtheria
Interventions
S315, 0.9% Sodium Chloride (NaCl)
Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

NCT02140281
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A (cefadroxil alone), Treatment B - AZD1722 followed by cefadroxil
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Days to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

NCT00908271
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

Experimental Study to Validate the Modified Glucose Disposal Test

NCT01152372
View directory record Official record
Conditions
Diabetes
Interventions
Insulin, glucose and staple isotopes
Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 21, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies

NCT00055575
View directory record Official record
Conditions
Mood Disorders, Healthy, Unipolar Depression, Bipolar Depression
Interventions
Scopolamine Nasal Spray
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

NCT01915901
View directory record Official record
Conditions
Healthy
Interventions
bismuth subsalicylate (Pepto-Bismol®), matching placebo (bismuth subsalicylate), dimethyl fumarate (DMF)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

NCT05277012
View directory record Official record
Conditions
Healthy Participants
Interventions
Etrumadenant
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 21, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

NCT01737892
View directory record Official record
Conditions
Asthma
Interventions
Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

NCT01616277
View directory record Official record
Conditions
Healthy
Interventions
PF-06252616, Placebo, PF-06252161
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects

NCT00336739
View directory record Official record
Conditions
Healthy
Interventions
cinacalcet
Drug
Lead sponsor
Tufts University
Other
Eligibility
45 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2007 · Synced Oct 21, 2026, 10:13 AM EDT